Florida Cancer Specialists Showcase Integrated Oncology at NCODA Summit 2025
The 2025 NCODA International Fall Summit taking place this week provides a prominent platform for Florida Cancer Specialists & Research Institute (FCS) to present their latest findings on integrated oncology. With representation from physician leaders and pharmacy experts, the event emphasizes the importance of patient-centered care in cancer treatment.
FCS, known for its commitment to advancing oncology practices, is host to this significant summit. At the forefront is Dr. Lucio N. Gordan, the managing physician and president of FCS, who serves on the NCODA Board of Directors and Executive Council. As a key figure at the summit, he aims to foster knowledge and share practical tools that enhance patient care across the organization’s extensive practice.
Throughout the summit, attendees can expect a variety of informative sessions. Dr. Gordan will deliver the opening remarks, setting the tone for a day filled with discussions and presentations rooted in innovation and patient focus. Among the featured speakers is Chris Elder, PharmD, BCOP, FCS's Associate Director of Pharmacy Clinical Services, who will reveal the recipient of the 2025 Living the Mission Award and will also discuss groundbreaking treatments for anal canal cancer, such as ZYNYZ® (retifanlimab-dlwr).
Paul Chadwick, FCS’s chief value procurement officer, highlighted the significance of collaboration among healthcare providers to share best practices. He emphasized that such interactions not only promote optimal care outcomes for patients but also strengthen professional networks within the oncology community.
The contributions of FCS extend beyond the summit. Ahead of the event, FCS leadership co-authored an article in NCODA's Oncolytics Today that reviews recent advances in cancer treatment technologies, emphasizing the role of next-generation sequencing in personalizing care for patients with lung, colorectal, breast, and prostate cancers.
FCS’s Rx To Go is their in-house pharmacy offering personalized support for patients undergoing oral chemotherapy. The pharmacy has received multiple accreditations including URAC and ACHC, ensuring that it meets the highest standards in specialized pharmaceutical care.
As a leading force in oncology, FCS is poised to continue shaping the future of cancer care. Their innovative spirit is evident in their robust clinical research programs, which not only provide access to cutting-edge treatments for cancer patients but also play a crucial role in the approval of new therapies through clinical trials.
With FCS as a forerunner in integrating healthcare advancements, the summit serves as a vital reminder of the ongoing commitment to improving patient outcomes through collaboration, innovation, and continuous learning within the oncology community.
In conclusion, the participation of FCS in the NCODA International Fall Summit showcases their leadership role in advancing patient-centered cancer care. The insights shared during this event will likely lead to enhanced practices across various oncology settings, ensuring that patients receive the maximum benefit from their treatment journeys. By uniting healthcare providers and fostering a collaborative atmosphere, FCS continues to redefine the landscape of cancer care, paving the way for a healthier future for patients battling cancer.
FCS, known for its commitment to advancing oncology practices, is host to this significant summit. At the forefront is Dr. Lucio N. Gordan, the managing physician and president of FCS, who serves on the NCODA Board of Directors and Executive Council. As a key figure at the summit, he aims to foster knowledge and share practical tools that enhance patient care across the organization’s extensive practice.
Throughout the summit, attendees can expect a variety of informative sessions. Dr. Gordan will deliver the opening remarks, setting the tone for a day filled with discussions and presentations rooted in innovation and patient focus. Among the featured speakers is Chris Elder, PharmD, BCOP, FCS's Associate Director of Pharmacy Clinical Services, who will reveal the recipient of the 2025 Living the Mission Award and will also discuss groundbreaking treatments for anal canal cancer, such as ZYNYZ® (retifanlimab-dlwr).
Paul Chadwick, FCS’s chief value procurement officer, highlighted the significance of collaboration among healthcare providers to share best practices. He emphasized that such interactions not only promote optimal care outcomes for patients but also strengthen professional networks within the oncology community.
The contributions of FCS extend beyond the summit. Ahead of the event, FCS leadership co-authored an article in NCODA's Oncolytics Today that reviews recent advances in cancer treatment technologies, emphasizing the role of next-generation sequencing in personalizing care for patients with lung, colorectal, breast, and prostate cancers.
FCS’s Rx To Go is their in-house pharmacy offering personalized support for patients undergoing oral chemotherapy. The pharmacy has received multiple accreditations including URAC and ACHC, ensuring that it meets the highest standards in specialized pharmaceutical care.
As a leading force in oncology, FCS is poised to continue shaping the future of cancer care. Their innovative spirit is evident in their robust clinical research programs, which not only provide access to cutting-edge treatments for cancer patients but also play a crucial role in the approval of new therapies through clinical trials.
With FCS as a forerunner in integrating healthcare advancements, the summit serves as a vital reminder of the ongoing commitment to improving patient outcomes through collaboration, innovation, and continuous learning within the oncology community.
In conclusion, the participation of FCS in the NCODA International Fall Summit showcases their leadership role in advancing patient-centered cancer care. The insights shared during this event will likely lead to enhanced practices across various oncology settings, ensuring that patients receive the maximum benefit from their treatment journeys. By uniting healthcare providers and fostering a collaborative atmosphere, FCS continues to redefine the landscape of cancer care, paving the way for a healthier future for patients battling cancer.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.